S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Mesirow Orchestrates Sale of Harloff Manufacturing to Capsa Healthcare

The Winsford Company has finalized the sale of its subsidiary, Harloff Manufacturing, to global healthcare technology firm Capsa Healthcare. Chicago-based financial services firm Mesirow acted as the lead sell-side advisor for the transaction, successfully aligning Harloff’s clinical storage portfolio with Capsa’s broader suite of pharmacy automation and point-of-care solutions.

Mesirow Orchestrates Sale of Harloff Manufacturing to Capsa Healthcare
Photo: Bio & News

Founded in 1951, Colorado Springs-based Harloff has established itself as a critical supplier for hospitals, nursing homes, and pharmacies, specializing in clinical storage cabinets and medication carts. The acquisition allows Capsa Healthcare to integrate these assets into its existing platform, a move expected to streamline clinical workflows and create significant cross-selling potential across various medical care settings.

John Calcagnini, Managing Director at Mesirow Investment Banking, noted that the deal creates a highly complementary product ecosystem. Tim Sweetland, President of Winsford II, credited the Mesirow team for their strategic guidance throughout the negotiation process, highlighting the synergy between the two entities as a primary driver for future innovation. Stout Capital supported the transaction as a co-advisor, marking another milestone for Mesirow’s healthcare practice, which has now executed over 350 deals in recent years.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!